BACKGROUND: High attrition rates among African-Americans (AA) volunteers are a persistent problem that makes clinical trials less representative and complicates estimation of treatment outcomes. Many studies contrast AA with other ethnic/racial groups, but few compare the AA volunteers who remain in treatment with those who leave. Here, in addition to comparing patterns of attrition between African Americans and Whites, we identify predictors of overall and early attrition among African Americans. METHOD: Sample comprised non-Hispanic African-American (n = 673) and White (n = 2,549) participants in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Chi-square tests were used to examine racial group differences in reasons for exit. Multivariate logistic regression was used to examine predictors of overall attrition, early attrition (by level 2) and top reasons cited for attrition among African Americans. RESULTS: Both African-American and White dropouts most commonly cited noncompliance reasons for attrition during the earlier phases of the study, while citing reasons related to efficacy and medication side effects later in the study. Satisfaction with treatment strongly predicted overall attrition among African Americans independent of socioeconomic, clinical, medical or psychosocial factors. Early attrition among African American dropouts was associated with less psychiatric comorbidity, and higher perceived physical functioning but greater severity of clinician-rated depression. CONCLUSIONS: Compliance, efficacy, and side effects are important factors that vary in relative importance during the course of a clinical trial. For African Americans in such trials, retention strategies should be broadened to emphasize patient engagement and satisfaction during the critical periods immediately following enrollment and treatment initiation.
BACKGROUND: High attrition rates among African-Americans (AA) volunteers are a persistent problem that makes clinical trials less representative and complicates estimation of treatment outcomes. Many studies contrast AA with other ethnic/racial groups, but few compare the AA volunteers who remain in treatment with those who leave. Here, in addition to comparing patterns of attrition between African Americans and Whites, we identify predictors of overall and early attrition among African Americans. METHOD: Sample comprised non-Hispanic African-American (n = 673) and White (n = 2,549) participants in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Chi-square tests were used to examine racial group differences in reasons for exit. Multivariate logistic regression was used to examine predictors of overall attrition, early attrition (by level 2) and top reasons cited for attrition among African Americans. RESULTS: Both African-American and White dropouts most commonly cited noncompliance reasons for attrition during the earlier phases of the study, while citing reasons related to efficacy and medication side effects later in the study. Satisfaction with treatment strongly predicted overall attrition among African Americans independent of socioeconomic, clinical, medical or psychosocial factors. Early attrition among African American dropouts was associated with less psychiatric comorbidity, and higher perceived physical functioning but greater severity of clinician-rated depression. CONCLUSIONS: Compliance, efficacy, and side effects are important factors that vary in relative importance during the course of a clinical trial. For African Americans in such trials, retention strategies should be broadened to emphasize patient engagement and satisfaction during the critical periods immediately following enrollment and treatment initiation.
Authors: Diane Warden; Madhukar H Trivedi; Stephen R Wisniewski; Lori Davis; Andrew A Nierenberg; Bradley N Gaynes; Sidney Zisook; Steven D Hollon; G K Balasubramani; Robert Howland; Maurizio Fava; Jonathan W Stewart; A John Rush Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: Stephen R Wisniewski; A John Rush; G K Balasubramani; Madhukar H Trivedi; Andrew A Nierenberg Journal: J Psychiatr Pract Date: 2006-03 Impact factor: 1.325
Authors: Jane L Givens; Thomas K Houston; Benjamin W Van Voorhees; Daniel E Ford; Lisa A Cooper Journal: Gen Hosp Psychiatry Date: 2007 May-Jun Impact factor: 3.238
Authors: Diane Warden; A John Rush; Stephen R Wisniewski; Ira M Lesser; Susan G Kornstein; G K Balasubramani; Michael E Thase; Sheldon H Preskorn; Andrew A Nierenberg; Elizabeth A Young; Kathy Shores-Wilson; Madhukar H Trivedi Journal: Int J Neuropsychopharmacol Date: 2008-07-09 Impact factor: 5.176
Authors: Ira M Lesser; Daniel B Castro; Bradley N Gaynes; Jodi Gonzalez; A John Rush; Jonathan E Alpert; Madhukar Trivedi; James F Luther; Stephen R Wisniewski Journal: Med Care Date: 2007-11 Impact factor: 2.983
Authors: Hector M González; Thomas Croghan; Brady West; David Williams; Randolph Nesse; Wassim Tarraf; Robert Taylor; Ladson Hinton; Harold Neighbors; James Jackson Journal: Psychiatr Serv Date: 2008-10 Impact factor: 4.157
Authors: Philip Cheng; Annemarie I Luik; Cynthia Fellman-Couture; Edward Peterson; Christine L M Joseph; Gabriel Tallent; Kieulinh Michelle Tran; Brian K Ahmedani; Timothy Roehrs; Thomas Roth; Christopher L Drake Journal: Psychol Med Date: 2018-05-24 Impact factor: 7.723
Authors: Michelle S Hamstra; Victoria L Pemberton; Nicholas Dagincourt; Danielle Hollenbeck-Pringle; Felicia L Trachtenberg; James F Cnota; Andrew M Atz; Elizabeth Cappella; Sylvia De Nobele; Josephine Grima; Martha King; Rosalind Korsin; Linda M Lambert; Meghan K MacNeal; Larry W Markham; Gretchen MacCarrick; Donna M Sylvester; Patricia Walter; Mingfen Xu; Ronald V Lacro Journal: Clin Trials Date: 2020-08-21 Impact factor: 2.486